Insomnia Severity Index (ISI): A Complete Guide to This Clinical Screening Tool

The Insomnia Severity Index (ISI) is a brief, validated self-report questionnaire designed to measure the nature, severity, and functional impact of insomnia symptoms. Developed by Charles M. Morin, Ph.D., a leading sleep researcher at Université Laval in Canada, the ISI was first published in 2001 and has since become one of the most widely used screening and outcome-tracking instruments in sleep medicine and behavioral health.

The ISI consists of seven items that assess key dimensions of the insomnia experience over the preceding two weeks. Unlike comprehensive polysomnographic evaluations or multi-hour clinical interviews, the ISI can be completed in approximately two to five minutes, making it a practical tool for routine clinical screening, treatment monitoring, and research applications.

The instrument was designed to align with the diagnostic criteria for insomnia disorder — both as conceptualized in the DSM-5-TR (where it is classified as Insomnia Disorder, code 780.52 / G47.00) and in the International Classification of Sleep Disorders (ICSD-3). While it is not a diagnostic instrument on its own, the ISI efficiently captures the core subjective dimensions that clinicians evaluate when assessing insomnia: difficulty initiating sleep, difficulty maintaining sleep, early morning awakening, dissatisfaction with sleep, interference with daytime functioning, noticeability of impairment to others, and personal distress about sleep problems.

The ISI measures perceived insomnia severity across seven specific domains, each rated on a 5-point Likert scale ranging from 0 (no problem) to 4 (very severe problem). The seven items assess:

• Difficulty falling asleep (sleep onset insomnia) — How much trouble does the person have getting to sleep at the beginning of the night?
• Difficulty staying asleep (sleep maintenance insomnia) — How frequently does the person wake during the night and struggle to return to sleep?
• Early morning awakening — Does the person wake up significantly earlier than intended and find themselves unable to fall back asleep?
• Satisfaction with current sleep pattern — How content or discontent is the person with their overall sleep quality?
• Interference with daily functioning — To what extent do sleep difficulties impair concentration, memory, energy, mood, or occupational and social performance during the day?
• Noticeability of impairment to others — How apparent are the consequences of poor sleep to the people around the individual?
• Distress or worry caused by the sleep problem — How much emotional distress — including anxiety, frustration, or helplessness — does the person experience because of their insomnia?

This structure reflects the biopsychosocial model of insomnia, capturing not only the nocturnal symptoms (items 1–3) but also the daytime consequences (items 5–6) and subjective appraisal (items 4 and 7) that are central to the clinical definition of insomnia disorder. The DSM-5-TR specifies that insomnia disorder requires both a sleep complaint and associated daytime distress or impairment, and the ISI directly taps into both of these dimensions.

Notably, the ISI measures subjective perception of insomnia rather than objective sleep parameters such as total sleep time measured by actigraphy or polysomnography. This is clinically appropriate because subjective sleep disturbance and associated distress are the primary drivers of treatment-seeking behavior and are the targets of frontline treatments like Cognitive Behavioral Therapy for Insomnia (CBT-I).

The ISI was originally developed and validated in adult populations and is most commonly used with individuals aged 18 and older. It is appropriate for use across a wide range of clinical and community settings:

• Primary care — as a rapid screen for insomnia symptoms during routine health visits
• Sleep medicine clinics — as part of a comprehensive sleep evaluation
• Psychiatric and psychological practice — to assess insomnia that co-occurs with depression, anxiety, PTSD, substance use disorders, and other mental health conditions
• Research settings — as a standardized outcome measure in clinical trials evaluating pharmacological and behavioral insomnia treatments
• Occupational health and military medicine — to screen for sleep disturbance in high-risk populations

The ISI has been validated across diverse populations including older adults, individuals with comorbid medical conditions (such as chronic pain and cancer), military veterans, and people with co-occurring psychiatric disorders. It has been translated into numerous languages — including French, Spanish, Chinese, Korean, Portuguese, and many others — with validation studies supporting its cross-cultural reliability.

While the ISI is primarily designed for adults, modified versions and related instruments exist for pediatric and adolescent populations. Clinicians working with children and adolescents typically use age-appropriate instruments or adapt clinical interviews rather than relying on the standard ISI.

The ISI is suitable for individuals who can read and comprehend questionnaire items at approximately a fifth-grade reading level, making it accessible to the general adult population. For individuals with literacy limitations or cognitive impairment, a clinician can administer the items verbally.

The ISI is a paper-and-pencil or digital self-report questionnaire. The respondent reads each of the seven items and selects a response from 0 to 4. The entire process takes two to five minutes, and scoring is straightforward:

Scoring: The total score is calculated by summing the responses across all seven items. The total score ranges from 0 to 28.

Interpretation thresholds established by Morin and colleagues are as follows:

• 0–7: No clinically significant insomnia — Sleep patterns are within normal limits and do not warrant clinical intervention.
• 8–14: Subthreshold insomnia — Some insomnia symptoms are present and may warrant monitoring, sleep hygiene counseling, or brief intervention, but do not meet the threshold for a clinical diagnosis.
• 15–21: Clinical insomnia (moderate severity) — Symptoms are consistent with insomnia disorder and are likely causing meaningful distress and functional impairment. Clinical intervention is generally recommended.
• 22–28: Clinical insomnia (severe) — Significant insomnia with substantial impact on functioning and well-being. Prompt clinical evaluation and treatment are strongly indicated.

These cutoff scores were derived from validation studies comparing ISI scores to clinician-rated insomnia diagnoses. A score of 10 is commonly used as the optimal screening cutoff to detect the presence of insomnia disorder (balancing sensitivity and specificity), while a score of 15 is widely used as the threshold for moderate clinical insomnia requiring treatment. Some research groups use an 8-point reduction in ISI total score as a benchmark for clinically meaningful treatment response, and a post-treatment score below 8 as the threshold for insomnia remission.

The ISI can be administered at a single time point for screening purposes or repeatedly over time to track treatment progress. In CBT-I protocols, it is standard practice to administer the ISI at baseline, during treatment, at post-treatment, and at follow-up intervals to quantify symptom change.

The ISI has been subjected to extensive psychometric evaluation and is considered one of the most well-validated self-report measures of insomnia severity available. Key psychometric properties include:

Internal consistency: Studies consistently report Cronbach's alpha values in the range of 0.74 to 0.91, indicating good to excellent internal consistency. This means the seven items reliably measure a coherent underlying construct of insomnia severity.

Test-retest reliability: The ISI demonstrates adequate temporal stability over short intervals (typically one to two weeks), with test-retest correlation coefficients reported in the range of 0.65 to 0.84. This is important for its use as a repeated measure — scores are stable enough to be meaningful at a single time point but sensitive enough to detect genuine change over time.

Convergent validity: ISI scores correlate significantly with other established measures of insomnia and sleep quality, including the Pittsburgh Sleep Quality Index (PSQI), sleep diary parameters (such as sleep onset latency, wake after sleep onset, and total sleep time), and clinician-rated insomnia severity. Correlations with these measures typically fall in the moderate to strong range (r = 0.50–0.80).

Discriminant validity: The ISI discriminates effectively between individuals with and without insomnia disorder as determined by structured clinical interviews. It also differentiates among severity levels, with scores systematically increasing across groups classified as good sleepers, subthreshold insomnia, and clinical insomnia.

Sensitivity to change: One of the ISI's most important clinical properties is its strong sensitivity to treatment-related change. Research demonstrates that ISI scores decrease significantly following evidence-based interventions (particularly CBT-I and pharmacotherapy), and effect sizes for pre-to-post treatment change are typically large (Cohen's d > 0.8). This makes the ISI an excellent outcome measure for clinical trials and routine clinical monitoring.

Factor structure: Factor analytic studies have generally supported a model with either one overarching insomnia severity factor or two correlated factors — one reflecting nocturnal symptoms (items 1–3) and one reflecting daytime impact and distress (items 4–7). Both structures are clinically meaningful and support the total score as a valid summary index.

The ISI's psychometric strengths have been confirmed across clinical populations including individuals with chronic pain, cancer, depression, anxiety disorders, PTSD, and other comorbidities, supporting its broad applicability.

In clinical practice, the ISI serves multiple interconnected functions:

1. Initial screening and detection. In primary care and behavioral health settings, the ISI is used as a first-line screening tool to identify patients who may have clinically significant insomnia. Because insomnia is highly prevalent — the DSM-5-TR estimates that approximately 6–10% of the general population meets criteria for insomnia disorder, and prevalence is significantly higher among individuals with psychiatric and medical comorbidities — systematic screening with a brief tool like the ISI helps ensure that insomnia is not overlooked.

2. Guiding clinical decision-making. ISI scores help clinicians determine the appropriate level of intervention. A patient scoring in the subthreshold range (8–14) might benefit from sleep hygiene education and brief behavioral counseling, while a patient scoring in the moderate-to-severe range (15–28) is more likely to benefit from structured treatment such as CBT-I — the recommended first-line treatment for chronic insomnia per the American Academy of Sleep Medicine (AASM) and the American College of Physicians (ACP). ISI scores also help clinicians decide when to consider pharmacological interventions or specialist referral.

3. Treatment outcome monitoring. The ISI is routinely administered at multiple time points during treatment to track progress. Clinicians can determine whether a patient is responding to intervention, has reached remission (typically defined as a score below 8), or requires a change in treatment approach. This measurement-based care model is increasingly recognized as best practice in behavioral health.

4. Research and clinical trials. The ISI is one of the most commonly used primary and secondary outcome measures in insomnia treatment research. Its brevity, strong psychometric properties, and sensitivity to change make it ideal for this purpose. Regulatory bodies and research consortiums recognize it as a standard measure in sleep research.

5. Integrated care settings. Because insomnia frequently co-occurs with mood disorders, anxiety, PTSD, chronic pain, and substance use disorders, the ISI is valuable in integrated behavioral health settings where sleep and mental health are assessed together. Tracking insomnia severity alongside measures of depression (such as the PHQ-9) and anxiety (such as the GAD-7) provides a more complete clinical picture.

Despite its strong psychometric foundation and wide clinical utility, the ISI has several important limitations that clinicians and researchers should keep in mind:

• It is a screening tool, not a diagnostic instrument. The ISI identifies the presence and severity of insomnia symptoms but does not establish a formal diagnosis. A comprehensive clinical evaluation — including medical history, psychiatric assessment, and consideration of other sleep disorders (such as obstructive sleep apnea, restless legs syndrome, or circadian rhythm disorders) — is necessary for accurate diagnosis. A high ISI score may reflect sleep disruption caused by another sleep disorder, medication effects, substance use, or medical conditions rather than primary insomnia disorder.
• It relies entirely on subjective self-report. While subjective experience is a central component of insomnia, individuals may overestimate or underestimate their sleep difficulties. People with insomnia commonly experience a phenomenon called sleep state misperception, where they perceive themselves as being awake when objective measures indicate they are asleep. The ISI does not capture objective sleep architecture or physiology.
• It does not assess the full range of sleep disorders. The ISI is specific to insomnia symptoms and does not screen for hypersomnia, parasomnias, sleep-related breathing disorders, or circadian rhythm disturbances. It should be used alongside a broader clinical assessment when the differential diagnosis includes these conditions.
• Cultural and contextual factors may influence responses. Although the ISI has been validated in multiple languages and cultures, subjective norms about what constitutes "good sleep," acceptable levels of daytime impairment, and comfort with disclosing sleep problems vary across populations. Clinicians should interpret scores in context.
• Limited utility for certain populations. The ISI was developed for adults and may not be appropriate for children, individuals with significant cognitive impairment, or those who cannot accurately self-report. Adaptations or alternative measures may be needed for these groups.
• Recall period and response bias. The ISI asks respondents to rate symptoms over the past two weeks, which requires retrospective recall. Memory biases, current mood state, and recent sleep experiences can disproportionately influence responses. Concurrent use of a daily sleep diary can help mitigate this limitation.

The Insomnia Severity Index is available in the public domain for clinical and research use. It was originally published in:

Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011). The Insomnia Severity Index: Psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep, 34(5), 601–608.

The questionnaire itself can be found in the appendices of this and earlier publications by Morin and colleagues. It is also available through:

• The Canadian Sleep and Circadian Network (CSCN) and other academic sleep research organizations
• Published treatment manuals for CBT-I, many of which reproduce the ISI with permission
• Electronic health record (EHR) systems — many healthcare systems have integrated the ISI into their digital platforms for routine administration
• Research repositories and open-access supplements in sleep medicine journals

Clinicians and researchers should note that while the ISI is freely available for non-commercial use, they should verify current usage permissions and cite the original source appropriately. Translations into specific languages should be sourced from validated translation studies to ensure psychometric integrity.

For clinical settings considering digital administration, the ISI integrates well with tablet-based and online survey platforms. Digital administration produces scores equivalent to paper administration and offers the added advantage of automated scoring and trend tracking over time.

While the ISI is an excellent standalone screening instrument, optimal insomnia assessment typically involves integrating it with other clinical tools and methods:

• Sleep diaries: A daily sleep log completed over one to two weeks provides a night-by-night record of sleep onset latency, number and duration of awakenings, total sleep time, and sleep quality. Sleep diaries complement the ISI by providing prospective, detailed data rather than retrospective summary estimates.
• Pittsburgh Sleep Quality Index (PSQI): The PSQI is a 19-item self-report measure that assesses overall sleep quality across seven component scores. It captures a broader range of sleep-related domains than the ISI and is often used alongside it in comprehensive assessments.
• Actigraphy: Wrist-worn actigraphy devices provide objective estimates of sleep-wake patterns over days to weeks. While not a substitute for polysomnography, actigraphy offers ecological data that can complement the ISI's subjective assessment.
• Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS): This measure assesses maladaptive cognitions about sleep that are common in chronic insomnia and are direct targets of CBT-I. Pairing it with the ISI helps clinicians understand the cognitive maintenance factors driving insomnia.
• Comorbidity screening: Given the strong bidirectional relationship between insomnia and mental health conditions, administering depression (PHQ-9), anxiety (GAD-7), and trauma (PCL-5) screeners alongside the ISI is standard best practice in integrated care.

The ISI functions as one component of a thorough clinical assessment. It provides a reliable, efficient, and sensitive measure of insomnia severity that complements — but does not replace — clinical judgment, comprehensive history-taking, and, when indicated, objective sleep studies.

If you are experiencing persistent sleep difficulties — trouble falling asleep, staying asleep, or waking too early — that occur at least three nights per week for three months or longer and are causing daytime distress or impairment, these patterns are consistent with what the DSM-5-TR defines as Insomnia Disorder, and professional evaluation is strongly recommended.

You should also seek evaluation if:

• Your sleep problems are accompanied by loud snoring, gasping, or breathing pauses during sleep (which may indicate a sleep-related breathing disorder)
• You experience excessive daytime sleepiness that puts you at risk for accidents
• Your sleep difficulties co-occur with significant depression, anxiety, or other mental health symptoms
• You are using alcohol, over-the-counter sleep aids, or other substances to manage sleep on a regular basis
• Your sleep problems are significantly affecting your work, relationships, or quality of life

A qualified healthcare provider — including primary care physicians, psychiatrists, psychologists, and sleep medicine specialists — can conduct a comprehensive evaluation, determine whether your symptoms align with insomnia disorder or another sleep condition, and recommend evidence-based treatment. Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line recommended treatment for chronic insomnia and has strong evidence for producing lasting improvements without the side effects associated with long-term medication use.

The information in this article is educational and does not constitute a clinical diagnosis or treatment recommendation. If you have concerns about your sleep, consult a licensed healthcare professional for a personalized evaluation.